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Drugs: blanket ban or harm reduction?
As the commercial success of electronic cigarettes offers the opportunity to 
study harm reduction by replacement therapy, the UK government steers in the 
opposite direction and plans to expand the ‘war on drugs’ with a blanket ban on 
all psychoactive substances. Michael Gross reports.The streets of London and other cities, 
along with summer music festivals, 
have recently witnessed a booming 
trade with balloons. Rather than with 
air or helium, these are filled with 
nitrous oxide, also known as laughing 
gas. Street traders can buy the 
gas in capsules available for cream 
dispensers, fill it into balloons and sell 
them for £3 to revellers in search of a 
bit of chemically-induced hilarity. 
While the use of laughing gas 
appears to have been a growing fad 
last summer, it is by no means a new 
phenomenon. Medical students and 
members of the aristocracy used the 
gas to lighten up their parties over 
200 years ago, and even the use of 
balloons for this purpose goes back to 
the 1970s. 
The gas is known to be harmless, 
which is why it is commercially 
available for food production and 
widely used as an anaesthetic in 
childbirth. Fearless reporters who 
have tried the balloon-dispensing 
method in the street describe the 
resulting high as “barely there” with no 
consequences. The very few people 
who died after experimenting with 
industrial quantities of nitrous oxide 
were the victims of a lack of oxygen 
(and excess stupidity) rather than a 
psychoactive substance. So inhaling 
the gas from balloons is just harmless 
fun that nobody can argue with, right? 
The UK’s new Conservative 
government has announced new 
legislation to ban all psychoactive 
substances as a matter of principle, 
with specific exceptions made 
for established trades like coffee, 
alcoholic drinks, and tobacco. 
Intended to break out of the race 
against the creative development 
of new ‘legal highs’, the draft bill 
debated in the House of Lords on 
June 9th would ban entirely harmless 
diversions, like breathing in laughing 
gas, along with everything else that 
influences our minds. More importantly, the plan 
undermines all plans for harm 
reduction in the drugs field, a strategy 
favoured by neuroscientists like 
David Nutt. The current commercial 
breakthrough of electronic cigarettes, 
or e-cigarettes, could provide a model 
of how drug replacement could work 
and what kind of scientific information 
would be required to ensure its 
success. 
A new age of steam 
Invented in China and first patented 
in 2003, e-cigarettes have become a 
major commercial success in recent 
years after manufacturers gave up the 
attempts to make them look like real 
cigarettes and offered opportunities 
to fine-tune the inhalation experience. 
They all include a battery-powered 
heating element that vaporises a liquid 
containing the nicotine and additional 
flavours. Modern (‘third generation’) 
vaporisers tend to be elaborate 
refillable devices with transparent 
tanks and a variable power setting. 
Legislators, health officials and 
science have been left trailing behind 
as the e-cigarette boom took off. So 
far, legislation around the world varies 
chaotically from total bans to complete 
absence of regulation. The issue is 
complicated by the fact that two 
powerful economic interest groups — 
the tobacco and the pharmaceutical 
industries — offer competing products, 
but could be tempted to enter the 
market themselves. Thus, they may 
lobby governments against or for 
e-cigarettes depending on whether or 
not they have decided to engage with 
the new technology. There is very little 
product standardisation, and science 
is only just beginning to explore the 
potential of the devices for smoking 
cessation and their own risks. 
In principle, the expectation is 
that smokers can reduce their risk 
exposure significantly by switching 
from the tobacco-burning to the Current Biology 25, R523–R548, June 29, 2015vaporising kind of nicotine intake. This 
is simply because most of the damage 
that smoking does is not due to the 
nicotine as such but to the tar-like 
condensation products that smokers 
inhale with the smoke and that settle 
in the airways. These condensates 
contain the substances that cause 
cancers and heart disease. By 
contrast, the electronic version does 
not involve any combustion and no 
chemical reaction with unwanted side 
products. What people breathe in is 
the mixture of chemicals that is in their 
liquid tank, so as long as those are 
safe, the process should be safe. One 
study that found dangerous levels of 
aldehyde in e-cigarette steam (N. Engl. 
J. Med. (2015) 372, 392–394) was 
recently shown to rely on unrealistic 
conditions (Addiction (2015) http://
dx.doi.org/10.1111/add.12942). While 
it is possible to produce this result, the 
associated ‘vaping’ experience would 
be sufficiently unpleasant to ensure 
that users don’t get exposed to these 
aldehydes. 
Based on the general assumption 
that smoking-associated harm mostly 
originates from combustion products 
and on the first emerging studies 
of e-cigarette safety, experts have 
Laughing gas: After two hundred years of use, 
the UK government plans to ban the use of 
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in whipped cream and during childbirth. This 
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Building steam: Electronic cigarettes have seen a remarkable commercial success in recent 
years. Their usefulness in smoking cessation remains a subject of debate but offers the opportu-
nity for scientific investigation into harm reduction by drug replacement. (Photo: TBEC Review.)estimated that harm reduction will 
be at least 95% compared with the 
uptake of the same amount of nicotine 
through conventional smoking. Thus, 
encouraging smokers to switch could 
save many thousands of lives. 
Critics of this assessment have 
expressed concern that the increasing 
visibility of e-cigarettes might 
encourage people who have never 
smoked to take up the electronic habit, 
such that their additional risk exposure 
would have to be balanced against the 
risk reduction of smokers switching. 
Given the arithmetic, however, it 
would take 20 non-smokers to take 
up e-cigarettes for every smoker who 
does to wipe out the benefits. Recent 
surveys show that there are hardly any 
users who come from the non-smoking 
side, so this fear appears to be 
unfounded at the moment. Advertising 
will of course have to be regulated to 
ensure that the industry does not try to 
entice children. 
The small residual risk of 
e-cigarettes is still an open field 
for research however, as a recent 
conference of the American Thoracic 
Society has shown, where a number 
of presentations covered preliminary 
investigations into the effects of vaping 
(http://conference.thoracic.org/2015/). 
One study, for instance, showed that 
the vaping exposure corresponding R524 Current Biology 25, R523–R548, Juneto the smoking of a single cigarette 
reduced the sensitivity of the cough 
reflex in an assay which uses an 
aerosol of capsaicin — the pungent 
substance in chilli peppers — to trigger 
coughing. Another presentation at the 
conference warned that the variability 
of device design and vaporisation 
conditions makes the medical effects 
unpredictable, as parameters such as 
coil temperature critically influence the 
composition of the vapour. 
Standardisation of such parameters 
will be an issue when legislators catch 
up with the burgeoning popularity of 
vaping. The government of Wales has 
recently announced a ban of vaping 
in enclosed public places, which has 
been criticised as disproportionate, 
given the low level of potential harm 
to users and bystanders. Other 
legislators, including the European 
Commission, are also reportedly 
preparing regulatory measures which 
may include the classification of 
solutions with high concentrations 
of nicotine — more than 20 mg/ml, 
such as smokers would use as a help 
in giving up — as medical products, 
which would then be subject to 
much tighter regulations than simple 
consumer products. 
As public opinion is still in flux, 
research remains in its infancy, 
and legal frameworks still need to  29, 2015 ©2015 Elsevier Ltd All rights reservedbe written, it is unclear whether 
e-cigarettes will eventually make a 
big contribution to further reduce 
the prevalence of conventional 
smoking and its associated health 
problems. There appears to be a 
unique opportunity for science to 
study and accompany a large-scale 
drug replacement that users undergo 
voluntarily. Fundamental questions of 
drug addiction, such as what part of 
the behaviour is caused by the actual 
substance and what part by the social 
context, could be more easily studied 
with e-cigarettes, where the exposure 
is readily tuneable. 
They could also serve as a model 
for the handling of other drugs that 
cause health issues. For instance, 
neurobiologist David Nutt, former 
drugs advisor to the UK government, 
has long argued to classify drugs 
on the basis of the actual harm they 
cause and to make harm reduction the 
guiding principle of drugs policy.  In his 
research at Imperial College London, 
he is investigating safe alternatives to 
alcohol.
Reduce no harm
At this crucial junction in the history 
of drug use, as large-scale harm 
reduction appears to be within reach, 
the new UK government has stunned 
observers by storming off in exactly 
the opposite direction. Within weeks 
of coming to office, it proposed a new 
law that will impose a blanket ban on 
all substances that might in any way 
“affect the emotional state” of a user. 
Under the Psychoactive Substances 
Bill, first debated in the House of Lords 
on June 9th, production, sale and 
provision (although not possession) 
of all psychoactive substances will 
be banned, with exemptions made 
only for specific product groups 
including alcoholic drinks, coffee, and 
nicotine, as well as for medicines and 
homeopathic products. 
The draft bill has been widely 
criticised for its sweeping definitions, 
which risk banning all substances 
that could provide any kind of 
harmless pleasures. The text defines 
psychoactive substances as follows: 
“For the purposes of this Act a 
substance produces a psychoactive 
effect in a person if, by stimulating 
or depressing the person’s central 
nervous system, it affects the person’s 
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 Altered emotions: Under the UK government’s proposed Psychoactive Substances Bill any 
product emitting a smell that affects our emotional state qualifies as a psychoactive substance, 
except if it serves as food or medicine. Strictly interpreted, that definition would include prod-
ucts like fragrant flowers, candles, air fresheners, and many of the things on display in this shop. 
(Photo: Cha già José.)mental functioning or emotional state;
and references to a substance’s 
psychoactive effects are to be read 
accordingly. For the purposes of this 
Act a person consumes a substance 
if the person causes or allows the 
substance, or fumes given off by the 
substance, to enter the person’s body
in any way.” 
Several observers have argued 
that this definition includes activities 
like smelling the fragrance of a 
flower or using any other product 
that evokes a mental response by 
its smell. The barrister and blogger 
Matthew Scott has argued in the Dail
Telegraph that: “Any substance which
gives pleasure, of course, ‘affects 
a person’s emotional state’. The 
starting point of the Bill is that giving 
pleasure is sufficient justification for 
prohibition.” 
Psychoactive substances as defined
by the bill lurk everywhere in our daily 
lives. “Butane gas, glue, petrol and 
some cleaning fluids have all been 
used for their psychoactive properties
As a result, the law as currently 
drafted will render their sale illegal. 
Indeed the Bill’s artificial definition of 
the word ‘consumption’ to include 
inhaling ‘fumes’ could have been 
designed to criminalise petrol station 
operators and hardware stores,” Scott
notes. Ironically, e-cigarette refills with
nicotine would be legal under the bill 
(due to the exemption for nicotine 
products, as long as they don’t contai
any other psychoactive substances), 
while those without might be banned 
from sale. 
Robert Winston from Imperial 
College London called the draft 
bill “ludicrous” and “a thoroughly 
bad bill”. The entrepreneur Richard 
Branson, who has engaged with a 
global campaign to stop the futile 
‘war on drugs’, called the draft bill 
“an astonishing example of the 
continued madness of the drug wars” 
and concluded: “If our goal is to keep 
our children out of harm’s way, the 
Psychoactive Substances Bill will 
achieve the opposite effect.”
David Nutt has expressed his 
concern that the additional prohibition
measures could further hamper brain 
science in the UK, adding to the 
severe limitations already imposed by 
the existing prohibition of the Misuse 
of Drugs Act 1971 (Curr. Biol. (2013) . 
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23, R585–R588). Amanda Feilding, 
director of the Beckley foundation, 
which supports medical research into 
psychoactive drugs, also expressed 
this concern. 
Moreover, the overall direction of 
the bill is the exact opposite to the 
rational strategy of treating drug 
misuse as a medical problem and 
scaling responses according to the 
actual harm that drugs do, with 
the overall aim of harm reduction, 
as favoured by scientific experts 
including Nutt and Feilding. The root 
cause of the explosive growth in new, 
untested ‘legal highs’ is in the fact 
that well-known and relatively benign 
substances, including cannabis, are 
widely prohibited. A legalised and 
regulated supply of mild drugs, as is 
currently emerging in several US states 
including Alaska, Washington, Oregon 
and Colorado, as well as in Uruguay, 
would remove much of the incentive to 
play catch with the law by developing 
new substances. 
At the first parliamentary debate 
on the bill, held in the House of Lords 
on June 9th, Lord Paddick from the 
Liberal Democrats criticised the 
draft bill severely and outlined the 
alternative: “We believe that there 
should be a health-based approach, 
aimed at reducing harm caused by Current Biology 25, R523–R548, June 29, 2015drug misuse, rather than a legalistic 
approach that is likely to further 
criminalise drug users. Successive 
governments have gradually eroded 
the link between criminal penalties and 
the harm caused by drugs by ignoring 
the scientific evidence and the advice 
that they have been given, to the 
extent that the drug laws in the UK are 
no longer considered by many people 
to have any credibility.” 
The clearest evidence that the 
government is blissfully unconcerned 
with the evaluation of actual harm 
that drugs do is its explicit inclusion 
of laughing gas in the prohibitions 
of the law. This inclusion clearly 
supports Scott’s assertion that UK 
home secretary “Theresa May wants 
to ban pleasure”. One could dismiss 
the bill as an obviously ridiculous 
fantasy of politicians removed from 
science and reality, but the unintended 
consequence of the bill, if it becomes 
law, will be that more people will 
get their (no longer legal) highs from 
criminal traders and run a higher risk 
of dying from tampered or mislabelled 
products. And this will be no laughing 
matter. 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
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